Prognostic and predictive indicators in operable breast cancer

Alessandro Morabito, Elena Magnani, Massimo Gion, Roberta Sarmiento, Barbara Capaccetti, Raffaele Longo, Domenico Gattuso, Giampietro Gasparini

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

Because of its biological heterogeneity and wide spectrum of responsiveness to different treatments, breast cancer is a complex disease of difficult clinical management. Over the past several years, knowledge of the molecular mechanisms regulating normal and aberrant cell growth leading to cancer has been enhanced. These advances have enabled the identification of an increasing number of surrogate biomarkers, which have been correlated with prognosis or used as predictors of response to specific treatments. Axillary nodal status, age, tumor size, pathologic grade, and hormone receptor status are the established prognostic and/or predictive factors for selection of adjuvant treatments. The role of new biomarkers, such as p53, HER2/neu, angiogenesis, and the proliferation index value, is promising; however, the clinical value of their determination must be provided by prospective clinical studies.

Original languageEnglish
Pages (from-to)381-390
Number of pages10
JournalClinical Breast Cancer
Volume3
Issue number6
Publication statusPublished - 2003

Fingerprint

Biomarkers
Breast Neoplasms
Neoplasms
Hormones
Prospective Studies
Growth
Clinical Studies

Keywords

  • Angiogenesis
  • Axillary nodal status
  • Biomarkers
  • HER2/neu
  • Hormone receptor
  • p53
  • Proliferation index

ASJC Scopus subject areas

  • Cancer Research

Cite this

Morabito, A., Magnani, E., Gion, M., Sarmiento, R., Capaccetti, B., Longo, R., ... Gasparini, G. (2003). Prognostic and predictive indicators in operable breast cancer. Clinical Breast Cancer, 3(6), 381-390.

Prognostic and predictive indicators in operable breast cancer. / Morabito, Alessandro; Magnani, Elena; Gion, Massimo; Sarmiento, Roberta; Capaccetti, Barbara; Longo, Raffaele; Gattuso, Domenico; Gasparini, Giampietro.

In: Clinical Breast Cancer, Vol. 3, No. 6, 2003, p. 381-390.

Research output: Contribution to journalArticle

Morabito, A, Magnani, E, Gion, M, Sarmiento, R, Capaccetti, B, Longo, R, Gattuso, D & Gasparini, G 2003, 'Prognostic and predictive indicators in operable breast cancer', Clinical Breast Cancer, vol. 3, no. 6, pp. 381-390.
Morabito A, Magnani E, Gion M, Sarmiento R, Capaccetti B, Longo R et al. Prognostic and predictive indicators in operable breast cancer. Clinical Breast Cancer. 2003;3(6):381-390.
Morabito, Alessandro ; Magnani, Elena ; Gion, Massimo ; Sarmiento, Roberta ; Capaccetti, Barbara ; Longo, Raffaele ; Gattuso, Domenico ; Gasparini, Giampietro. / Prognostic and predictive indicators in operable breast cancer. In: Clinical Breast Cancer. 2003 ; Vol. 3, No. 6. pp. 381-390.
@article{18e26f96348b47d49c4a3b3fd9731135,
title = "Prognostic and predictive indicators in operable breast cancer",
abstract = "Because of its biological heterogeneity and wide spectrum of responsiveness to different treatments, breast cancer is a complex disease of difficult clinical management. Over the past several years, knowledge of the molecular mechanisms regulating normal and aberrant cell growth leading to cancer has been enhanced. These advances have enabled the identification of an increasing number of surrogate biomarkers, which have been correlated with prognosis or used as predictors of response to specific treatments. Axillary nodal status, age, tumor size, pathologic grade, and hormone receptor status are the established prognostic and/or predictive factors for selection of adjuvant treatments. The role of new biomarkers, such as p53, HER2/neu, angiogenesis, and the proliferation index value, is promising; however, the clinical value of their determination must be provided by prospective clinical studies.",
keywords = "Angiogenesis, Axillary nodal status, Biomarkers, HER2/neu, Hormone receptor, p53, Proliferation index",
author = "Alessandro Morabito and Elena Magnani and Massimo Gion and Roberta Sarmiento and Barbara Capaccetti and Raffaele Longo and Domenico Gattuso and Giampietro Gasparini",
year = "2003",
language = "English",
volume = "3",
pages = "381--390",
journal = "Clinical Breast Cancer",
issn = "1526-8209",
publisher = "Elsevier",
number = "6",

}

TY - JOUR

T1 - Prognostic and predictive indicators in operable breast cancer

AU - Morabito, Alessandro

AU - Magnani, Elena

AU - Gion, Massimo

AU - Sarmiento, Roberta

AU - Capaccetti, Barbara

AU - Longo, Raffaele

AU - Gattuso, Domenico

AU - Gasparini, Giampietro

PY - 2003

Y1 - 2003

N2 - Because of its biological heterogeneity and wide spectrum of responsiveness to different treatments, breast cancer is a complex disease of difficult clinical management. Over the past several years, knowledge of the molecular mechanisms regulating normal and aberrant cell growth leading to cancer has been enhanced. These advances have enabled the identification of an increasing number of surrogate biomarkers, which have been correlated with prognosis or used as predictors of response to specific treatments. Axillary nodal status, age, tumor size, pathologic grade, and hormone receptor status are the established prognostic and/or predictive factors for selection of adjuvant treatments. The role of new biomarkers, such as p53, HER2/neu, angiogenesis, and the proliferation index value, is promising; however, the clinical value of their determination must be provided by prospective clinical studies.

AB - Because of its biological heterogeneity and wide spectrum of responsiveness to different treatments, breast cancer is a complex disease of difficult clinical management. Over the past several years, knowledge of the molecular mechanisms regulating normal and aberrant cell growth leading to cancer has been enhanced. These advances have enabled the identification of an increasing number of surrogate biomarkers, which have been correlated with prognosis or used as predictors of response to specific treatments. Axillary nodal status, age, tumor size, pathologic grade, and hormone receptor status are the established prognostic and/or predictive factors for selection of adjuvant treatments. The role of new biomarkers, such as p53, HER2/neu, angiogenesis, and the proliferation index value, is promising; however, the clinical value of their determination must be provided by prospective clinical studies.

KW - Angiogenesis

KW - Axillary nodal status

KW - Biomarkers

KW - HER2/neu

KW - Hormone receptor

KW - p53

KW - Proliferation index

UR - http://www.scopus.com/inward/record.url?scp=0037303970&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037303970&partnerID=8YFLogxK

M3 - Article

C2 - 12636883

AN - SCOPUS:0037303970

VL - 3

SP - 381

EP - 390

JO - Clinical Breast Cancer

JF - Clinical Breast Cancer

SN - 1526-8209

IS - 6

ER -